Orion Portfolio Solutions LLC Has $1.49 Million Stock Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Orion Portfolio Solutions LLC lifted its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 359.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 94,282 shares of the company's stock after acquiring an additional 73,758 shares during the period. Orion Portfolio Solutions LLC's holdings in Dr. Reddy's Laboratories were worth $1,489,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in RDY. JPMorgan Chase & Co. increased its holdings in Dr. Reddy's Laboratories by 462.1% during the 4th quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company's stock worth $44,444,000 after purchasing an additional 2,313,987 shares in the last quarter. GQG Partners LLC grew its holdings in shares of Dr. Reddy's Laboratories by 359.7% during the fourth quarter. GQG Partners LLC now owns 2,008,759 shares of the company's stock worth $31,718,000 after buying an additional 1,571,808 shares in the last quarter. Segall Bryant & Hamill LLC bought a new position in shares of Dr. Reddy's Laboratories during the fourth quarter worth about $712,000. Prudential Financial Inc. lifted its stake in Dr. Reddy's Laboratories by 250.8% in the 4th quarter. Prudential Financial Inc. now owns 135,400 shares of the company's stock valued at $2,138,000 after acquiring an additional 96,800 shares in the last quarter. Finally, Angeles Investment Advisors LLC lifted its stake in Dr. Reddy's Laboratories by 341.1% in the 4th quarter. Angeles Investment Advisors LLC now owns 18,597 shares of the company's stock valued at $294,000 after acquiring an additional 14,381 shares in the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy's Laboratories Stock Down 1.2 %

Shares of NYSE RDY traded down $0.16 during mid-day trading on Tuesday, hitting $12.43. The company had a trading volume of 3,057,634 shares, compared to its average volume of 1,370,165. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The firm has a 50-day simple moving average of $13.26 and a two-hundred day simple moving average of $14.43. The company has a market capitalization of $10.37 billion, a PE ratio of 19.79 and a beta of 0.51. Dr. Reddy's Laboratories Limited has a one year low of $12.28 and a one year high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, equities analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Analysts Set New Price Targets

Separately, Nomura lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.